Understanding health economic analysis in critical care: Insights from recent randomized controlled trials

Current Opinion in Critical Care

Volumn 17, Issue 5, 2011, Pages 504-509

  Sud, Sachin ^a,b   Cuthbertson, Brian H ^b  

^a CREDIT VALLEY HOSPITAL   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

cost effectiveness; critical care; health economic analysis

Indexed keywords

CLINICAL PRACTICE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; CRITICALLY ILL PATIENT; HEALTH CARE PLANNING; HEALTH ECONOMICS; HUMAN; INTENSIVE CARE; MORTALITY; PATIENT CARE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESOURCE MANAGEMENT; REVIEW;

COSTS AND COST ANALYSIS; CRITICAL CARE; HUMANS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 80052745712     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0b013e32834a4bc1     Document Type: Review

References (55)

1. Halpern NA, Pastores SM. Critical care medicine in the United States 2000-2005: an analysis of bed numbers, occupancy rates, payer mix, and costs. Crit Care Med 2010; 38:65-71.
2. Halpern NA. Can the costs of critical care be controlled? Curr Opin Crit Care 2009; 15:591-596.
3. Kahn JM. Understanding economic outcomes in critical care. Curr Opin Crit Care 2006; 12:399-404. (Pubitemid 44341703)
4. Kahn JM, Angus DC. Reducing the cost of critical care: new challenges, new solutions. Am J Respir Crit Care Med 2006; 174:1167-1168. (Pubitemid 44924811)
5. Truog RD, Brock DW, Cook DJ, et al. Rationing in the intensive care unit. Crit Care Med 2006; 34:958-963; quiz 971.
6. Aaron HJ. Waste, we know you are out there. N Engl JMed 2008; 359:1865-1867.
7. Talmor D, Shapiro N, Greenberg D, et al. When is critical care medicine costeffective? A systematic review of the cost-effectiveness literature. Crit Care Med 2006; 34:2738-2747. (Pubitemid 44610938)
8. American Thoracic Society. Understanding costs and cost-effectiveness in critical care: report from the second American Thoracic Society workshop on outcomes research. Am J Respir Crit Care Med 2002; 165:540-550.
9. Lee CP, Chertow GM, Zenios SA. An empiric estimate of the value of life: updating the renal dialysis cost-effectiveness standard. Value Health 2009; 12:80-87.
10. World Heath Organziation. CHOosing Interventions that are Cost Effective (WHO-CHOICE). http://www.who.int/choice/costs/CER-levels/en/index.html. [Accessed 1 May 2011].
11. Coughlin MT, Angus DC. Economic evaluation of new therapies in critical illness. Crit Care Med 2003; 31:S7-16.
12. Cuthbertson BH, Rattray J, Campbell MK, et al. The PRaCTICaL study of nurse led, intensive care follow-up programmes for improving long term outcomes from critical illness: a pragmatic randomised controlled trial. BMJ 2009; 339:b3723.
13. Peek GJ, Elbourne D, Mugford M, et al. Randomised controlled trial and parallel economic evaluation of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR). Health Technol Assess 2010; 14:1-46.
14. Stevens K, McCabe C, Jones C, et al. The incremental cost effectiveness of withdrawing pulmonary artery catheters from routine use in critical care. Appl Health Econ Health Policy 2005; 4:257-264. (Pubitemid 43242214)
15. Harvey S, Harrison DA, Singer M, et al. Assessment of the clinical effectiveness of pulmonary artery catheters in management of patients in intensive care (PAC-Man): a randomised controlled trial. Lancet 2005; 366:472-477. (Pubitemid 41111695)
16. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709. (Pubitemid 32204987)
17. Siegel JP. Assessing the use of activated protein C in the treatment of severe sepsis. N Engl J Med 2002; 347:1030-1034.
18. Warren HS, Suffredini AF, Eichacker PQ, et al. Risks and benefits of activated protein C treatment for severe sepsis. N Engl J Med 2002; 347:1027-1030.
19. Angus DC, Linde-Zwirble WT, Clermont G, et al. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med 2003; 31:1-11. (Pubitemid 36151142)
20. Fowler RA, Hill-Popper M, Stasinos J, et al. Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis. J Crit Care 2003; 18:181-191; discussion 191-4. (Pubitemid 37413803)
21. Neilson AR, Burchardi H, Chinn C, et al. Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany. J Crit Care 2003; 18:217-227. (Pubitemid 38036903)
22. Costa V, Brophy JM. Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis. BMC Anesthesiol 2007; 7:5.
23. Manns BJ, Lee H, Doig CJ, et al. An economic evaluation of activated protein C treatment for severe sepsis. N Engl J Med 2002; 347:993-1000.
24. Peek GJ, Mugford M, Tiruvoipati R, et al. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomized controlled trial. Lancet 2009; 374:1351-1363.
25. Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000; 342:1301-1308.
26. Esteban A, Ferguson ND, Meade MO, et al. Evolution of mechanical ventilation in response to clinical research. Am J Respir Crit Care Med 2008; 177:170-177.
27. Young MP, Manning HL, Wilson DL, et al. Ventilation of patients with acute lung injury and acute respiratory distress syndrome: has new evidence changed clinical practice? Crit Care Med 2004; 32:1260-1265.
28. Wolthuis EK, Kesecioglu J, Hassink LH, et al. Adoption of lower tidal volume ventilation improves with feedback and education. Respir Care 2007; 52:1761-1766.
29. Cooke CR, Kahn JM, Watkins TR, et al. Cost-effectiveness of implementing low-tidal volume ventilation in patients with acute lung injury. Chest 2009; 136:79-88.
30. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl JMed 2001; 345:1368-1377.
31. Huang DT, Clermont G, Dremsizov TT, et al. Implementation of early goaldirected therapy for severe sepsis and septic shock: A decision analysis. Crit Care Med 2007; 35:2090-2100. (Pubitemid 47326446)
32. Ospina-Tascon GA, Buchele GL, Vincent JL. Multicenter, randomized, controlled trials evaluating mortality in intensive care: doomed to fail? Crit Care Med 2008; 36:1311-1322. (Pubitemid 351482683)
33. Aberegg SK, Richards DR, O'Brien JM. Delta inflation: a bias in the design of randomized controlled trials in critical care medicine. Crit Care 2010; 14:R77.
34. Sud S, Friedrich JO, Taccone P, et al. Prone ventilation reduces mortality in patients with acute respiratory failure and severe hypoxemia: systematic review and meta-analysis. Intensive Care Med 2010; 36:585-599.
35. Vincent JL. We should abandon randomized controlled trials in the intensive care unit. Crit Care Med 2010; 38:S534-S538.
36. Sud S, Sud M, Friedrich JO, et al. High frequency oscillation in patients with acute lung injury and acute respiratory distress syndrome (ARDS): systematic review and meta-analysis. BMJ 2010; 340:c2327.
37. Riker RR, Shehabi Y, Bokesch PM, et al. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JAMA 2009; 301:489-499.
38. Dasta JF, Kane-Gill SL, Pencina M, et al. A cost-minimization analysis of dexmedetomidine compared with midazolam for long-term sedation in the intensive care unit. Crit Care Med 2010; 38:497-503.
39. Koo KK, Sun JC, Zhou Q, et al. Pulmonary artery catheters: Evolving rates and reasons for use. Crit Care Med 2011; 39:1613-1618.
40. Rossi C, Simini B, Brazzi L, et al. Variable costs of ICU patients: a multicenter prospective study. Intensive Care Med 2006; 32:545-552.
41. Cheung AM, Tansey CM, Tomlinson G, et al. Two-year outcomes, healthcare use, and costs of survivors of acute respiratory distress syndrome. Am J Respir Crit Care Med 2006; 174:538-544. (Pubitemid 44330546)
42. Dasta JF, McLaughlin TP, Mody SH, et al. Daily cost of an intensive care unit day: the contribution of mechanical ventilation. Crit Care Med 2005; 33:1266-1271. (Pubitemid 40827376)
43. Kahn JM, Rubenfeld GD, Rohrbach J, et al. Cost savings attributable to reductions in intensive care unit length of stay for mechanically ventilated patients. Med Care 2008; 46:1226-1233.
44. Al MJ, Hakkaart L, Tan SS, et al. Cost-consequence analysis of remifentanilbased analgo-sedation vs. conventional analgesia and sedation for patients on mechanical ventilation in The Netherlands. Crit Care 2010; 14:R195.
45. Cox CE, Reed SD, Govert JA, et al. Economic evaluation of propofol and lorazepam for critically ill patients undergoing mechanical ventilation. Crit Care Med 2008; 36:706-714.
46. Angus DC, Musthafa AA, Clermont G, et al. Quality-adjusted survival in the first year after the acute respiratory distress syndrome. Am J Respir Crit Care Med 2001; 163:1389-1394. (Pubitemid 32506604)
47. Cuthbertson BH, Roughton S, Jenkinson D, et al. Quality of life in the five years after intensive care: a cohort study. Crit Care 2010; 14:R6.
48. Dowdy DW, Eid MP, Sedrakyan A, et al. Quality of life in adult survivors of critical illness: a systematic review of the literature. Intensive Care Med 2005; 31:611-620. (Pubitemid 40684976)
49. Herridge MS, Tansey CM, Matte A, et al. Functional disability 5 years after acute respiratory distress syndrome. N Engl J Med 2011; 364:1293-1304.
50. Iwashyna TJ, Ely EW, Smith DM, et al. Long-term cognitive impairment and functional disability among survivors of severe sepsis. JAMA 2010; 304:1787-1794.
51. Quartin AA, Schein RM, Kett DH, et al. Magnitude and duration of the effect of sepsis on survival. Department of Veterans Affairs Systemic Sepsis Cooperative Studies Group. JAMA 1997; 277:1058-1063. (Pubitemid 27147544)
52. Unroe M, Kahn JM, Carson SS, et al. One-year trajectories of care and resource utilization for recipients of prolonged mechanical ventilation: a cohort study. Ann Intern Med 2010; 153:167-175.
53. Friedberg M, Saffran B, Stinson TJ, et al. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA 1999; 282:1453-1457. (Pubitemid 29493799)
54. Garattini L, Koleva D, Casadei G. Modeling in pharmacoeconomic studies: funding sources and outcomes. Int J Technol Assess Healthcare 2010; 26:330-333.
55. John-Baptiste A, Bell C. Industry sponsored bias in cost effectiveness analyses. BMJ 2010; 341:c5350.